O xidative stress is associated with human and some animal models of hypertension. [1] [2] [3] Superoxide anion (O 2 Ϫ ) is produced in the vasculature of hypertensive subjects, and O 2 Ϫ increases blood pressure in part by reducing the bioavailability of nitric oxide (NO). 1 Treatments that reduce vascular O 2 Ϫ levels have potential therapeutic application in the treatment of hypertension. 4, 5 However, data from studies of the effects of antioxidants in hypertensive subjects have been inconsistent. Acute treatment with ascorbic acid did not alter blood pressure in hypertensive patients 5 or in DOCAsalt hypertensive rats. 6 However, long-term treatment of hypertensive patients with ascorbic acid reduced systolic blood pressure. 4 The role of endothelial-derived NO in the effects of ascorbic acid on blood pressure are not clear, because ascorbic acid-induced blood vessel dilation are endothelium-independent. 5, 7 Superoxide dismutase (SOD) mimetic 4-hydroxy 2,2,6,6,-tetramethyl piperidine 1-oxyl (tempol) lowers blood pressure in normotensive and hypertensive rats. 6,8 -10 It has been recently reported that acute administration of tempol to normotensive or DOCA-salt and spontaneously hypertensive rats (SHRs) causes a decrease in sympathetic nervous system activity that is not prevented by nitric oxide synthase (NOS) inhibition. 6, 10, 11 Long-term tempol treatment attenuates hypertension development in several animal models of hypertension, and the antihypertensive actions were proposed to be caused by an improvement of endothelium function via reduction of oxidative stress. [12] [13] [14] [15] Recently, it has been shown that prevention by tempol of hypertension development in Dahl salt-sensitive rats or in ACTH-induced hypertension in rats is independent of an improvement in endothelium function and oxidative stress. 16, 17 Thus, these findings suggest that tempol has important pharmacological actions on sympathetic function and blood pressure that may not be related to the removal of O 2 Ϫ and/or increased NO availability. NAD(P)H oxidase is the major source of O 2 Ϫ in the vasculature. 2,3 Increased NAD(P)H oxidase activity mediates O 2 Ϫ production in angiotensin II (Ang II)-induced hypertension, 18 SHRs, 19 and DOCA-salt 20 hypertensive rats. In these animals, the mRNA for the NAD(P)H oxidase subunits p 22phox , gp 91phox , and nox-1 were greater than in normotensive rats. Apocynin, a NAD(P)H oxidase inhibitor, reduces O 2 Ϫ production and improves endothelium function in rat and human blood vessels 19, 21, 22 and attenuates DOCA-salt hypertension. 19 Pretreatment with the superoxide dismutasepolyethylene glycol (PEG-SOD), a membrane-permeable SOD analog, protects against myocardium ischemia/reperfusion injury by reducing O 2 Ϫ levels. 23 
Methods

General Procedures
Animal use protocols were approved by the All University Committee for Animal Use and Care at Michigan State University. Male Sprague-Dawley rats (Charles River Laboratories, Portage, Mich) with an initial weight of 175 to 225 grams were used in these studies. DOCA-salt hypertension was produced using previously published methods. 6, 25 Three to four weeks after uninephrectomy and DOCA pellet implantation or sham surgery, rats were anesthetized with urethane (1.2 g/kg, intraperitoneally). Heart rate (HR), mean arterial blood pressure (MAP), and renal sympathetic nerve activity (RSNA) were recorded using methods that have been described in detail previously. 6, 9 Supplements of urethane were administered when required and the rats respired spontaneously.
Oxidative Fluorescent Microtopography
The thoracic aorta and vena cava were removed from DOCA-salt rats after tempol treatment (1000 mol/kg) for 5 minutes and were cut into 30-m-thick vertical sections using a cryostat. Dihydroethidium (1 mol/L) was topically applied to each tissue section. Slides were incubated in a light-protected humidified chamber at 37°C for 30 minutes. PEG-SOD (500 U/mL) was applied topically on some tissue sections as a positive control. Images were obtained using a laser scanning confocal microscope (Leica Instruments, Heidleberg, Germany) as described previously. 6 
Experimental Protocol
Effects of Tempol on HR, MAP, and RSNA in DOCA-Salt and Sham Rats
After surgical preparation of the rats, 30 to 40 minutes were allowed for stabilization of all variables. The effects of tempol (30, 100, and 300 mol/kg) on HR, MAP, and RSNA were examined after intravenous (IV) bolus administration to sham and DOCA-salt rats using an interdose interval of 30 to 60 minutes. Tempol doses were administered over a 1-minute period, and each variable was monitored for 20 minutes after tempol treatment. To study the effects of tempol on vascular O 2 Ϫ levels, the thoracic aorta and vena cava were taken from DOCA-salt rats within 5 minutes after treatment with tempol (1000 mol/kg) or saline, because this was the time of peak effect. Vascular O 2 Ϫ levels were then measured using oxidative fluorescent microtopography.
Effects of Apocynin on MAP and HR in DOCA-Salt and Sham Rats
The effects of apocynin (200 mol/kg) on MAP and HR were studied after IV bolus administration in sham and DOCA-salt rats. Apocynin was dissolved in 6% dimethyl sulfoxide-saline to produce a 100-mmol/L stock solution. The effects of tempol on MAP and HR with or without of apocynin were tested in another group of sham and DOCA-salt rats. In these animals, tempol (300 mol/kg IV) was administered after 5 minutes of apocynin treatment.
Effects of PEG-SOD and SOD on HR and MAP in DOCA-Salt Rats
After recording basal MAP and HR, the effects of PEG-SOD (10 000 U/kg) or SOD (25 000 U/kg) IV administration on MAP and HR were studied in DOCA-salt rats. This dose of PEG-SOD reduces O 2 Ϫ levels and protects against cardiac ischemia/reperfusion injury in rats. 23, 24 The effects of PEG-SOD (5000 U/kg bolus followed by a 30-minute infusion of 500 U/kg per minute) or SOD (10 000 U/kg bolus followed by a 30-minute infusion of 1000 U/kg per minute) on MAP and HR were studied in 4 other DOCA-salt rats.
Statistics Analysis
All data are expressed as meanϮSE. The overall effects of tempol, apocynin, SOD, and PEG-SOD were evaluated using 1-way ANOVA with repeated measures. Differences between parameters before and after each treatment were evaluated using Student paired t test comparing control responses to those obtained after each treatment. PϽ0.05 was the level of statistical significance.
Results
A total 30 rats (9 sham and 21 DOCA-salt) were used for the studies. At the time of the experiments, the body weight of sham rats was 425Ϯ15 grams and 330Ϯ20 grams in DOCAsalt rats. The baseline MAP under urethane anesthesia was significantly higher in DOCA-salt rats than in sham rats (140Ϯ5 mm Hg versus 98Ϯ6 mm Hg; PϽ0.01), but there were no differences in HR between sham and DOCA-salt rats (420Ϯ15 bpm versus 425Ϯ16 bpm; PϾ0.05).
Effects of Tempol on HR, MAP, RSNA, and Vascular O 2 ؊ Levels
Tempol (100 and 300 mol/kg) transiently decreased HR, MAP, and RSNA in sham and DOCA-salt rats (Figure 1, 2) . Peak responses occurred within 5 minutes after tempol administration. In DOCA-salt rats, tempol caused a larger decrease in MAP than in sham rats. At 300 mol/kg, tempol reduced MAP from 140Ϯ5 mm Hg to 80Ϯ6 mm Hg and from 98Ϯ4 mm Hg to 74Ϯ4 mm Hg in DOCA-salt and sham rats (Ϫ43%Ϯ5% versus Ϫ24%Ϯ3%; PϽ0.01) (Figure 2 ). Tempol-induced decreases in HR and RSNA were similar in DOCA-salt and sham rats ( Figure 2 ). HR decreased from 435Ϯ15 bpm to 390Ϯ12 bpm in DOCA-salt rats, and from 420Ϯ12 bpm to 383Ϯ16 bpm in sham rats. RSNA was inhibited by 50%Ϯ7% and 40Ϯ9% from baseline in DOCAsalt and sham rats, respectively ( Figure 2 ). All parameters recovered to baseline levels within 15 minutes of tempol administration. Tempol (1000 mol/kg) did not reduce O 2 Ϫ levels in the aorta or vena cava from DOCA-salt rats compared with vessels from saline-treated DOCA-salt rats. However, in the same rats, tempol lowered blood pressure from 142Ϯ4 mm Hg to 75Ϯ3 mm Hg, and RSNA was inhibited by 60% from baseline (nϭ3 in each group) (Figure 3 ). PEG-SOD (500 U/mL) applied topically to the blood vessel sections reduced dihydroethidium fluorescence markedly in the aorta and vena cava.
Effects of Apocynin, SOD, and PEG-SOD on MAP and HR in DOCA-Salt Rats
At resting MAP (140Ϯ6 mm Hg), apocynin (200 mol/kg) did not lower MAP or HR (Table) . Apocynin also did not potentiate depressor responses caused by tempol, because the effects of tempol on MAP and HR were similar before and after apocynin treatment in sham and DOCA-salt rats (Figure 4) . PEG-SOD (10 000 U/kg) or SOD (25 000 U/kg) did not change MAP or HR significantly in DOCA-salt rats (Table) . SOD (5000 U/kg bolus followed by a 30-minute infusion of 500 U/kg per minute; nϭ4) or PEG-SOD (10,000 U/kg bolus followed by a 30-minutes infusion of 1000 U/kg per minute; nϭ3) did not lower MAP or change HR in DOCA-salt rats (141Ϯ4 mm Hg versus 138Ϯ5 mm Hg and 425Ϯ15 bpm versus 415Ϯ16 bpm, respectively).
Discussion
Superoxide anion is one of several reactive oxygen species produced in the vasculature of hypertensive animals and humans. It contributes to high blood pressure by quenching endogenous NO and reducing the levels of this vasodilator substance. 26 Ϫ or inhibiting its synthesis will increase the bioavailability of NO and will reduce the activity of the signaling mechanisms activated by O 2 Ϫ to increase vascular tone. In previous studies and in the present work, we showed that acute treatment of DOCA-salt rats with tempol, an O 2 Ϫ scavenger, decreased blood pressure, HR, and RSNA. Shokoji 10 have recently reported similar results in studies of SHRs. It is reasonable to suggest that tempol lowers blood pressure in these animals by reducing O 2 Ϫ levels in the vasculature, in the sympathetic nervous system, or perhaps in both tissues. However, we found that acute treatment with tempol did not reduce O 2 Ϫ in the aorta or the vena cava from DOCA-salt rats. We also found that acute treatment with apocynin, a NAD(P)H oxidase inhibitor, did not change blood pressure and did not potentiate depressor responses caused by tempol in DOCA-salt rats. Because O 2 Ϫ is a very short-lived molecule, inhibition of its synthesis by apocynin should cause a rapid decrease in O 2 Ϫ levels; therefore, blood pressure should also decrease rapidly. Finally, we found that acute treatment with SOD and PEG-SOD did not alter blood pressure in DOCA-salt rats. Both of these enzymes rapidly degrade O 2 Ϫ . 22, 23, 29 Acute administration of tempol produced a rapid but brief decrease in RSNA and blood pressure in anesthetized DOCA-salt and SHRs. 6, 9, 10 Depressor responses in hypertensive rats were greater than in sham rats, 6, 10 because the sympathetic nervous system plays an important role in maintaining the elevated blood pressure in these models. 30 However, intracerebroventricular injection of tem- Figure 2 . Effects of tempol on HR, MAP, and RSNA in DOCAsalt and sham rats (nϭ5 in each group). Depressor responses were significantly increased in DOCA-salt rats, whereas decreases in HR and RSNA were not altered. All measurements were made 2 to 4 minutes after tempol administration, because this was the time of peak effect. Data are expressed as a percent change from the baseline level measured just before each tempol dose. Data are meanϮSE. *Significantly different from baseline levels (PϽ0.05). #Significantly different from sham rats (PϽ0.05). 
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pol failed to alter MAP, HR, and RSNA in SHRs, 10 suggesting that tempol acted peripherally to cause sympatho-inhibition. Interestingly, Shokoji et al 10 recently reported that local application of tempol onto the renal sympathetic nerves caused a dose-dependent decrease in integrated RSNA without changing MAP and HR. They also showed that NOS inhibition did not alter basal RSNA or modify the tempol-induced reduction in RSNA. 31 The data indicate that tempol directly inhibits peripheral sympathetic nerves, possibly by inhibiting sympathetic neuroeffector transmission. O 2 Ϫ reacts with NO to form peroxynitrite, thereby reducing tissue levels of NO. However, we have shown previously that the effects of acute tempol treatment on blood pressure and sympathetic nerve activity are NO-independent. 6, 9, 11 It should be noted that acute treatment with antioxidants, other than tempol, does not lower blood pressure. For example, ascorbic acid does not lower blood pressure in hypertensive patients 5 or in DOCA-salt hypertensive rats. 6 The antioxidants SOD and tiron quench, by Ͼ70%, O 2 Ϫ signals measured using lucigenin-enhanced chemiluminescence in human saphenous vein and internal mammary artery. 29 However, acute treatment with tiron did not alter blood pressure in normotensive or hypertensive rats. 6, 32 Apocynin, a NAD(P)H oxidase inhibitor, dose-dependently relaxed human pre-constricted internal mammary arterial and saphenous venous rings via increased NO bioavailability, and this effect was larger than that caused by PEG-SOD. 22 Our study is the first to our knowledge to examine blood pressure responses caused by acute treatment of DOCA-salt rats with apocynin and PEG-SOD. We found that acute treatment with apocynin or with PEG-SOD at a dose that blocks O 2 Ϫ -induced ischemia/reperfusion injury 23, 24 did not alter blood pressure or potentiate depressor responses caused by tempol in DOCAsalt rats. Taken together, these data indicate that acute treatment with antioxidants does not lower blood pressure via a reduction in O 2 Ϫ in DOCA-salt hypertension. O 2 Ϫ is elevated in the aorta, vena cava, and mesenteric artery and vein from DOCA-salt rats compared to that in sham rats. 6, 27, 33 We found that acute treatment with tempol did not reduce O 2 Ϫ from aorta and vena cava in DOCA-salt rats, even though tempol lowered blood pressure and RSNA by Ϸ50%. However, the effects of tempol on blood pressure are extremely short, because tempol has a half-life time of 1 minute and it becomes undetectable within 6 minutes after administration in vivo. 34 Therefore, our failure to detect a tempol-induced reduction of O 2 Ϫ in the aorta and vena cava might be attributed to tempol's short duration of action.
PEG-SOD applied topically reduced O 2 Ϫ levels in aorta and vena cava from DOCA-salt rats, indicating that O 2 Ϫ in aorta and vena cava can be reduced by this antioxidant. Furthermore, SOD and PEG-SOD increase NO bioavailability in human preconstricted internal mammary arterial and saphenous venous rings 22 and afferent arteriolar in vitro. 35 Therefore, we used continuous intravenous infusions of SOD and PEG-SOD to determine if these antioxidants would lower blood pressure in DOCA-salt rats, because we expected that the duration of action of these enzymes might be longer than that of tempol. However, we found that prolonged treatment with SOD and PEG-SOD did not change blood pressure, HR, or RSNA in DOCAsalt of sham rats. PEG-SOD is a large molecule, and 30-minute infusion may be insufficient to allow enough of the enzyme to penetrate to interstitial sites and to quench O 2 Ϫ . Longer PEG-SOD treatments may be needed to reveal a depressor response and a reduction in O 2 Ϫ levels in the vasculature and/or in sympathetic ganglia.
Long-term tempol and apocynin administration prevents Ang-II-induced, 12 DOCA-salt, 13 ,20 ACTH-induced, 17 endothelininduced, 36 and Dahl salt-sensitive hypertension. 15 Data were obtained from the indicated number of animals (n) and are meansϮSE. HR indicates heart rate; MAP, mean arterial pressure; PEG-SOD, superoxide dismutase-polyethylene glycol, SOD, superoxide dismutasr.
*Significantly different from control levels. attenuates hypertension by reducing NAD(P)H oxidase-derived O 2 Ϫ in DOCA-salt rats. 20 NAD(P)H oxidase inhibition improves endothelial function, reduces O 2 Ϫ production, and increases eNOS activity and NO generation in human and rat blood vessels. 19, 22 In SHR and Ang II-infused rats, the antihypertensive action of tempol is blocked after NOS inhibition. 8, 37 Treatment with tempol reduces oxidative stress and improves endothelium function. 14, 15, 36 Interestingly, tempol attenuates ACTH-induced hypertension but does not reduce the ACTH-induced increases in plasma F(2)-isoprostanes (a marker of oxidative stress). 17 In addition, L-NAME does not attenuate tempol-induced depressor responses in Dahl salt-sensitive hypertensive rats. 16 These results suggest that tempol effects on ACTH-induced and Dahl salt-sensitive hypertension are independent of oxidative stress and endothelium function. Thus, all of the mechanisms for the antihypertensive effects of tempol have not been established.
Perspectives
Oxidative stress is prominent in human hypertension, and antioxidants have potential therapeutic applications for the treatment of hypertension and associated pathologies. Tempol, a drug that can scavenge O 2 Ϫ , lowers blood pressure after acute treatment of hypertensive rats, but this effect is not shared by other drugs (apocynin, SOD) known to reduce O 2 Ϫ levels in the vasculature. Tempol inhibits sympathetic nerve activity, suggesting that the antihypertensive effects of tempol may be mediated by direct inhibition of sympathetic input to the cardiovascular system. The mechanism by which tempol inhibits sympathetic neurons is not known. Our data also indicate that long-term treatment with antioxidant drugs will be required to reduce blood pressure in hypertensive subjects. Finally, the effects of O 2 Ϫ on the mechanisms controlling vascular tone must persist in the absence of elevated levels of O 2 Ϫ , because blood pressure did not decrease during acute treatment with apocynin, PEG-SOD, or SOD, which should produce at least a transient decrease in local O 2 Ϫ .
